Highest-materiality recent filing
Arcutis Q1 2026 revenue $105.4M (+65% YoY); net loss narrows to $11.3M
Net product revenue of $105.4M from ZORYVE, up 65% YoY but down 17% sequentially due to Q1 seasonality.
Arcutis Q4 2025 revenue $127.5M, first profitable quarter; 2026 guidance raised to $480-495M
Q4 net product revenue $127.5M (+84% YoY, +29% sequential); full year $372.1M (+123% YoY).
Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M
Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.
Arcutis Q2 product revenue $81.5M (+164% YoY); ZORYVE foam approved for scalp/body psoriasis
Net product revenue $81.5M vs $30.9M YoY, driven by ZORYVE portfolio demand across four approved indications.
Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO
Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.
Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025
Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.
Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M
Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.
Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)
Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.
Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M
ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.
Arcutis Q2 product revenue $30.9M, up 547% YoY; net loss narrows to $52.3M
ZORYVE franchise net product revenue $30.9M ($17.3M cream, $13.6M foam); 43% sequential growth.
Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M
Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.
Arcutis raises ~$161.6M in public offering of 18.2M shares at $9.50
Issued ~18.2M shares at $9.50 via underwritten public offering, raising ~$161.6M net.
Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.
On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.
On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings